ASCO Data Could Clarify Ocular Toxicity Concerns For ImmunoGen’s Mirvetuximab

Pivotal Trial Results And Pooled Safety Analysis Being Presented

 
• By Alaric DeArment
  
ImmunoGen is presenting data at ASCO on mirvetuximab soravtansine in platinum-resistant FRa-high ovarian cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences